FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- 4 Enemies of Bull Markets
- Experiencing Technical Difficulty?
- The Importance of Good Breadth
- How Big Money Rules the Markets
- Follow the Leader
- Mad Mail: Chesapeake Energy Is Hiring?
- Lightning Round: Royal Dutch Shell, Bank of America, RF Micro Devices and More
- Lightning Round OT: Harley-Davidson, Heartland Payment and More
- Cramer’s Christmas List
- Cramer: This Stock Offers ‘Plenty of Upside’
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Johnson & Johnson is about as close to a “buy and hold” name as Cramer will ever get. He was a fan back in the days when he worked at Goldman Sachs [GS
Loading...
()
], stayed loyal to the company while running his hedge fund and has been recommending the stock on Mad Money for the past four years. Still, if the company’s fundamentals changed at all, he’d sell J&J in a heartbeat.
That’s why Cramer doesn’t endorse “buy and hold” investing. When a stock isn’t working, he said, dump it. You can always buy it back later at a better price. This type of active money management is what smart investors do. So ignore the “professionals” who want you all in all the time. That’s just irresponsible.
But back to J&J [JNJ
Loading...
()
]. This is a strong health-care company with the ability to increase its dividend. That quality, above almost all others in this market, is what we want because earnings estimates can’t be trusted right now. A company that can throw more cash at shareholders, even in this recession, is worth consideration. And J&J qualifies.
Johnson & Johnson has increased its dividend for 46 years in a row, the last bump of 11% coming in early 2008. Considering the company’s cash-rich balance sheet, Cramer expects another increase this year as well.
The Mad Money host also likes J&J’s acquisitions of Mentor and Omrix. And while two big drugs lose patent protection this year, there’s still a product pipeline that bodes well for future earnings. Besides, Wall Street has been anticipating the patent losses, so that is already baked into the stock.
Another plus: J&J earns 49% of sales from overseas. That means the weaker dollar in international markets translates into more profits here at home.
The stock has plunged to $52 from $72, bringing the dividend yield up to 3.5%. Cramer likes that as an entry point, and he recommends buying more JNJ on the way down. This is a great long-term investment, he said. But remember to cash out the second it’s no longer working.
Cramer's charitable trust owns Goldman Sachs and Johnson & Johnson.
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes